However, the enteral lactoferrin supplementation significantly decreased the incidence of late-onset sepsis (RR = 0.55, 95% CI: 0.33 to 0.92, P = 0.02) and NEC stage II or III (RR = 0.42, 95% CI: 0.19 to 0.97, P = 0.04) after removing the largest trial (ELFIN Trial Investigators Group, 2019), although the effect on all-cause mortality (RR = 0.86, 95% CI: 0.37 to 1.97, P = 0.72) was similar to the overall analysis (Table S1). Here, LTF is linked to Sepsis.